Cost effectiveness of pre-operative gonadotrophin releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy.
OBJECTIVE
To conduct a cost effectiveness analysis of pre-operative gonadotrophin releasing hormone agonists (GnRHa) in women with uterine fibroids undergoing hysterectomy or myomectomy.


METHODS
A cost effectiveness analysis using the effectiveness data from a systematic review of GnRHa.


METHODS
Secondary care.


METHODS
Women with uterine fibroids undergoing hysterectomy or myomectomy and women volunteers.


METHODS
Effectiveness data were used from a systematic review to construct a model and to calculate the cost per surgical outcome avoided. In order to evaluate the value women place on the outcome, a willingness to pay analysis of women volunteers was undertaken.


METHODS
(a) The cost of avoiding abdominal hysterectomy and the cost of avoiding a vertical incision at either hysterectomy or myomectomy; (b) The value that women place on avoiding abdominal hysterectomy and on avoiding a vertical incision at either hysterectomy or myomectomy. All costs are in NZ dollars.


RESULTS
For hysterectomy, the additional cost of treatment with GnRHa was NZ$1190 per case. The cost of avoiding one abdominal procedure was NZ$4577 per case and the cost of avoiding one vertical incision was NZ$6263. For a myomectomy, the additional cost of treatment with GnRHa was NZ$1535 per case. The cost of avoiding one vertical incision was NZ$4651 per case. These costs exceeded the benefit women placed on the outcomes.


CONCLUSIONS
Although the pre-operative use of GnRHa results in benefits which include less frequent abdominal incisions in the case of hysterectomy and less frequent vertical incisions in the case of myomectomy, the benefits do not justify the costs. This study highlights the importance of considering both the benefits and costs in health care decisions.
Farquhar
Cynthia
C
Cochrane Menstrual Disorders and Subfertility Group, Department of Obstetrics and Gynaecology, National Women's Hospital, University of Auckland, New Zealand.
Brown
Paul M
PM
Furness
Sue
S
D003362:Cost-Benefit Analysis; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007044:Hysterectomy / Q000191:economics / Q000379:methods; D007889:Leiomyoma / Q000188:drug therapy / Q000191:economics / Q000601:surgery*; D009215:Myometrium / Q000601:surgery*; D009520:New Zealand; D011292:Premedication / Q000191:economics*; D011300:Preoperative Care / Q000191:economics / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012307:Risk Factors; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000191:economics / Q000601:surgery*
D007987:Gonadotropin-Releasing Hormone